Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download the poster here Poster Presentation
Category: TG1050
Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation Collaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux… Continue reading Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Transgene – Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
20181112 PR TG0150 Phase 1 data combi AASLD EN
Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Claire Fournier, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
20181010 AASLD Abstract Poster EN
Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
180820 – TG Tasly Closing EN
Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
180710 – TG Tasly agreement PR
First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
20180117 PR FPI T101
TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
20171023 PR post AASLD TG1050 final. docx
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
20171017 PR AASLD TG1050 final
